Ludwig Center Publications

2022

Chakraborty G, Nandakumar S, Hirani R, Nguyen B, Stopsack KH, Kreitzer C, Rajanala SH, Ghale R, Mazzu YZ, Pillarsetty NVK, Lee G-SM, Scher HI, Morris MJ, Traina T, Razavi P, Abida W, Durack JC, Solomon SB, Vander Heiden MG, Mucci LA, Wibmer AG, Schultz N, Kantoff PW. 2022. The impact of PIK3R1 mutations and insulin-PI3K-glycolytic pathway regulation in prostate cancer. Clin Cancer Res clincanres.4272.2021-12-1 23:41:01.777.

Dalin S, Grauman-Boss B, Lauffenburger DA, Hemann MT. 2022. Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse. Sci Rep 12:5453.

Datta R, Sivanand S, Lau AN, Florek LV, Barbeau AM, Wyckoff J, Skala MC, Vander Heiden MG. 2022. Interactions with stromal cells promote a more oxidized cancer cell redox state in pancreatic tumors. Sci Adv 8:eabg6383.

Davidson SM, Schmidt DR, Heyman JE, O’Brien JP, Liu AC, Israelsen WJ, Dayton TL, Sehgal R, Bronson RT, Freinkman E, Mak HH, Fanelli GN, Malstrom S, Bellinger G, Carracedo A, Pandolfi PP, Courtney KD, Jha A, DePinho RA, Horner JW, Thomas CJ, Cantley LC, Loda M, Vander Heiden MG. 2022. Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma. Cancer Res canres.CAN-21-2352-E.2021.

Franklin R, Guo Y, He S, Chen M, Ji F, Zhou X, Frankhouser D, Do BT, Chiem C, Jang M, Blanco MA, Vander Heiden MG, Rockne RC, Ninova M, Sykes DB, Hochedlinger K, Lu R, Sadreyev RI, Murn J, Volk A, Cheloufi S. 2022. Regulation of chromatin accessibility by the histone chaperone CAF-1 sustains lineage fidelity. Nat Commun 13:2350.

Gouirand V, Gicquel T, Lien EC, Jaune-Pons E, Da Costa Q, Finetti P, Metay E, Duluc C, Mayers JR, Audebert S, Camoin L, Borge L, Rubis M, Leca J, Nigri J, Bertucci F, Dusetti N, Lucio Iovanna J, Tomasini R, Bidaut G, Guillaumond F, Vander Heiden MG, Vasseur S. 2022. Ketogenic HMG-CoA lyase and its product β-hydroxybutyrate promote pancreatic cancer progression. EMBO J e110466.

Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, Rideout WM, Naranjo S, Fessenden T, Nguyen KB, Winter PS, Kohn RE, Westcott PMK, Schenkel JM, Shanahan S-L, Shalek AK, Spranger S, White FM, Jacks T. 2022. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature.

Kirkpatrick JD, Soleimany AP, Dudani JS, Liu H-J, Lam HC, Priolo C, Henske EP, Bhatia SN. 2022. Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis. Eur Respir J 59:2100664.

Li Z, Ji BW, Dixit PD, Tchourine K, Lien EC, Hosios AM, Abbott KL, Rutter JC, Westermark AM, Gorodetsky EF, Sullivan LB, Vander Heiden MG, Vitkup D. 2022. Cancer cells depend on environmental lipids for proliferation when electron acceptors are limited. Nat Metab. Jun;4(6):711-723.

Miettinen TP, Ly KS, Lam A, Manalis SR. 2022. Single-cell monitoring of dry mass and dry mass density reveals exocytosis of cellular dry contents in mitosis. eLife 11:e76664.

Patel RS, Romero R, Watson EV, Liang AC, Burger M, Westcott PMK, Mercer KL, Bronson RT, Wooten EC, Bhutkar A, Jacks T, Elledge SJ. A GATA4-regulated secretory program suppresses tumors through recruitment of cytotoxic CD8 T cells. Nature Comm. 2022 Jan 11;13(1):256.

Phelps GB, Hagen HR, Amsterdam A, Lees JA. 2022. MITF deficiency accelerates GNAQ-driven uveal melanoma. Proc Natl Acad Sci U S A 119:e2107006119.

Replogle JM, Saunders RA, Pogson AN, Hussmann JA, Lenail A, Guna A, Mascibroda L, Wagner EJ, Adelman K, Lithwick-Yanai G, Iremadze N, Oberstrass F, Lipson D, Bonnar JL, Jost M, Norman TM, Weissman JS. Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq. Cell. 2022 Jul 7;185(14):2559-2575.e28.

Rickelt S, Neyaz A, Condon C, Whittaker CA, Zaidi AH, Taylor MS, Abbruzzese G, Mattia AR, Zukerberg L, Shroff SG, Yilmaz OH, Yilmaz O, Wu EY, Choi W-T, Jobe BA, Odze RD, Patil DT, Deshpande V, Hynes RO. 2022. Agrin Loss in Barrett’s Esophagus-Related Neoplasia and Its Utility as a Diagnostic and Predictive Biomarker. Clin Cancer Res 28:1167–1179.

Yang D, Jones MG, Naranjo S, Rideout WM, Min KH (Joseph), Ho R, Wu W, Replogle JM, Page JL, Quinn JJ, Horns F, Qiu X, Chen MZ, Freed-Pastor WA, McGinnis CS, Patterson DM, Gartner ZJ, Chow ED, Bivona TG, Chan MM, Yosef N, Jacks T, Weissman JS. 2022. Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell.

Zhang Y, Donaher JL, Das S, Li X, Reinhardt F, Krall JA, Lambert AW, Thiru P, Keys HR, Khan M, Hofree M, Wilson MM, Yedier-Bayram O, Lack NA, Onder TT, Bagci-Onder T, Tyler M, Tirosh I, Regev A, Lees JA, Weinberg RA. 2022. Genome-wide CRISPR screen identifies PRC2 and KMT2D-COMPASS as regulators of distinct EMT trajectories that contribute differentially to metastasis. Nat Cell Biol.

2021

Abbott KL, Vander Heiden MG. 2021. The CAT-SIR is out of the bag: tumors prefer host rather than dietary nutrients. BMC Biol 19.

Bent EH, Millán-Barea LR, Zhuang I, Goulet DR, Fröse J, Hemann MT. 2021. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Nat Commun 12:6218.

Burger ML, Cruz AM, Crossland GE, Gaglia G, Ritch CC, Blatt SE, Bhutkar A, Canner D, Kienka T, Tavana SZ, Barandiaran AL, Garmilla A, Schenkel JM, Hillman M, de Los Rios Kobara I, Li A, Jaeger AM, Hwang WL, Westcott PMK, Manos MP, Holovatska MM, Hodi FS, Regev A, Santagata S, Jacks T. 2021. Antigen dominance hierarchies shape TCF1+ progenitor CD8 T cell phenotypes in tumors. Cell 184:4996-5014.e26. doi:10.1016/j.cell.2021.08.020

Concepcion CP, Ma S, LaFave LM, Bhutkar A, Liu M, DeAngelo LP, Kim JY, Priore ID, Schoenfeld AJ, Miller M, Kartha VK, Westcott PMK, Sanchez-Rivera FJ, Meli K, Gupta M, Bronson RT, Riely GJ, Rekhtman N, Rudin CM, Kim CF, Regev A, Buenrostro JD, Jacks T. 2021. SMARCA4 inactivation promotes lineage-specific transformation and early metastatic features in the lung. Cancer Discov. 

Dongre A, Rashidian M, Eaton EN, Reinhardt F, Thiru P, Zagorulya M, Nepal S, Banaz T, Martner A, Spranger S, Weinberg RA. 2021. Direct and Indirect Regulators of Epithelial–Mesenchymal Transition–Mediated Immunosuppression in Breast Carcinomas. Cancer Discov 11:1286–1305.

Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, Bezwada D, Blanc L, Prideaux B, Jin X, Possada JM, Chen J, Chin CR, Amoozgar Z, Ferreira R, Chen IX, Naxerova K, Ng C, Westermark AM, Duquette M, Roberge S, Lindeman NI, Lyssiotis CA, Nielsen J, Housman DE, Duda DG, Brachtel E, Golub TR, Cantley LC, Asara JM, Davidson SM, Fukumura D, Dartois VA, Clish CB, Jain RK, Vander Heiden MG. 2021. Fatty acid synthesis is required for breast cancer brain metastasis. Nature Cancer 1–15. 

Francescone R, Barbosa Vendramini-Costa D, Franco-Barraza J, Wagner J, Muir A, Lau AN, Gabitova L, Pazina T, Gupta S, Luong T, Rollins D, Malik R, Thapa RJ, Restifo D, Zhou Y, Cai KQ, Hensley HH, Tan Y, Kruger WD, Devarajan K, Balachandran S, Klein-Szanto AJ, Wang H, El-Deiry WS, Vander Heiden MG, Peri S, Campbell KS, Astsaturov I, Cukierman E. 2020. Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppression. Cancer Discov CD-20-0775.

Hajal C, Shin Y, Li L, Serrano JC, Jacks T, Kamm RD. 2021. The CCL2-CCR2 astrocyte-cancer cell axis in tumor extravasation at the brain. Sci Adv 7:eabg8139.

Hamza B, Miller AB, Meier L, Stockslager M, King EM, Ng SR, DeGouveia KL, Mulugeta N, Calistri NL, Strouf H, Lin L, Chin CR, Weinberg RA, Shalek AK, Jacks T, Manalis S. 2021. Measuring kinetics and metastatic propensity of CTCs by blood exchange between mice. Nat Commun.

Hao L, Rohani N, Zhao RT, Pulver EM, Mak H, Kelada OJ, Ko H, Fleming HE, Gertler FB, Bhatia SN. 2021. Microenvironment-triggered multimodal precision diagnostics. Nat Mater. 

He J, Nissim L, Soleimany AP, Binder-Nissim A, Fleming HE, Lu TK, Bhatia SN. 2021. Synthetic Circuit-Driven Expression of Heterologous Enzymes for Disease Detection. ACS Synth Biol 10:2231–2242.

Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. 2021. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci Immunol 6:eabi8800.

Iyer S, Zhang S, Yucel S, Horn H, Smith SG, Reinhardt F, Hoefsmit E, Assatova B, Casado J, Meinsohn M-C, Barrasa MI, Bell GW, Pérez-Villatoro F, Huhtinen K, Hynninen J, Oikkonen J, Galhenage PM, Pathania S, Hammond PT, Neel BG, Farkkila A, Pépin D, Weinberg RA. 2021. Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy. Cancer Discov 11:384–407. 

Jerby-Arnon L, Neftel C, Shore ME, Weisman HR, Mathewson ND, McBride MJ, Haas B, Izar B, Volorio A, Boulay G, Cironi L, Richman AR, Broye LC, Gurski JM, Luo CC, Mylvaganam R, Nguyen L, Mei S, Melms JC, Georgescu C, Cohen O, Buendia-Buendia JE, Segerstolpe A, Sud M, Cuoco MS, Labes D, Gritsch S, Zollinger DR, Ortogero N, Beechem JM, Petur Nielsen G, Chebib I, Nguyen-Ngoc T, Montemurro M, Cote GM, Choy E, Letovanec I, Cherix S, Wagle N, Sorger PK, Haynes AB, Mullen JT, Stamenkovic I, Rivera MN, Kadoch C, Wucherpfennig KW, Rozenblatt-Rosen O, Suvà ML, Riggi N, Regev A. 2021. Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med 27:289–300.

Katsikis G, Collis JF, Knudsen SM, Agache V, Sader JE, Manalis SR. 2021. Inertial and viscous flywheel sensing of nanoparticles. Nat Commun.

Keibler MA, Dong W, Korthauer KD, Hosios AM, Moon SJ, Sullivan LB, Liu N, Abbott KL, Arevalo OD, Ho K, Lee J, Phanse AS, Kelleher JK, Iliopoulos O, Coloff JL, Vander Heiden MG, Stephanopoulos G. 2021. Differential substrate use in EGF- and oncogenic KRAS-stimulated human mammary epithelial cells. FEBS J.

Kirkpatrick JD, Soleimany AP, Dudani JS, Liu H-J, Lam HC, Priolo C, Henske EP, Bhatia SN. 2021. Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis. Eur Respir J.

Lambert AW, Weinberg RA. 2021. Linking EMT programmes to normal and neoplastic epithelial stem cells. Nat Rev Cancer 1–14.

Lien EC, Vander Heiden MG. 2021. Pancreatic β cells put the glutamine engine in reverse. Cell Metab 33:702–704.

Lien EC, Westermark AM, Zhang Y, Yuan C, Li Z, Lau AN, Sapp KM, Wolpin BM, Vander Heiden MG. 2021. Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature 1–6.

Luengo A, Li Z, Gui DY, Sullivan LB, Zagorulya M, Do BT, Ferreira R, Naamati A, Ali A, Lewis CA, Thomas CJ, Spranger S, Matheson NJ, Vander Heiden MG. 2021. Increased demand for NAD+ relative to ATP drives aerobic glycolysis. Mol Cell.

Mueller HS, Fowler CE, Dalin S, Moiso E, Udomlumleart T, Garg S, Hemann MT, Lees JA. 2021. Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel. PNAS 118.

Pikman Y, Ocasio-Martinez N, Alexe G, Dimitrov B, Kitara S, Diehl FF, Robichaud AL, Conway AS, Ross L, Su A, Ling F, Qi J, Roti G, Lewis CA, Puissant A, Vander Heiden MG, Stegmaier K. 2021. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia 1–13.

Schenkel JM, Herbst RH, Canner D, Li A, Hillman M, Shanahan S-L, Gibbons G, Smith OC, Kim JY, Westcott P, Hwang WL, Freed-Pastor WA, Eng G, Cuoco MS, Rogers P, Park JK, Burger ME, Rozenblatt-Rosen O, Cong L, Pauken KE, Regev A, Jacks T. 2021. Conventional type I dendric cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes. Immunity S1074-7613(21)00360–5.

Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. 2021. Metabolomics in cancer research and emerging applications in clinical oncology. CA: A Cancer Journal for Clinicians.

Soleimany AP, Kirkpatrick JD, Su S, Dudani JS, Zhong Q, Bekdemir A, Bhatia SN. 2021. Activatable Zymography Probes Enable In Situ Localization of Protease Dysregulation in Cancer. Cancer Res 81:213–224.

Su XA, Ma D, Parsons JV, Replogle JM, Amatruda JF, Whittaker CA, Stegmaier K, Amon A. 2021. RAD21 is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress. Genes Dev.

Sullivan MR, Darnell AM, Reilly MF, Kunchok T, Joesch-Cohen L, Rosenberg D, Ali A, Rees MG, Roth JA, Lewis CA, Vander Heiden MG. 2021 Methionine synthase is essential for cancer cell proliferation in physiological folate environments. Nat Metab. 3(11):1500-1511.

Tian C, Huang Y, Clauser KR, Rickelt S, Lau AN, Carr SA, Vander Heiden MG, Hynes RO. 2021. Suppression of pancreatic ductal adenocarcinoma growth and metastasis by fibrillar collagens produced selectively by tumor cells. Nature Communications 12:2328.

Trakala M, Aggarwal M, Sniffen C, Zasadil L, Carroll A, Ma D, Su XA, Wangsa D, Meyer A, Sieben CJ, Zhong J, Hsu P, Paradis G, Ried T, Holland A, Deursen JV, Amon A. 2021. Clonal selection of stable aneuploidies in progenitor cells drives high-prevalence tumorigenesis. Genes Dev 35:1079–1092.

Wang RW, Viganò S, Ben-David U, Amon A, Santaguida S. 2021. Aneuploid senescent cells activate NF-κB to promote their immune clearance by NK cells. EMBO Rep 22:e52032.

Back to top of page

2020

Alkan HF, Vesely PW, Hackl H, Foßelteder J, Schmidt DR, Vander Heiden MG, Pichler M, Hoefler G, Bogner-Strauss JG. 2020. Deficiency of malate-aspartate shuttle component SLC25A12 induces pulmonary metastasis. Cancer Metab 8:26.

Benjamin DC, Kang JH, Hamza B, King EM, Lamar JM, Manalis SR, Hynes RO. 2020. YAP Enhances Tumor Cell Dissemination by Promoting Intravascular Motility and Re-entry into Systemic Circulation. Cancer Res canres.0212.2020.

Boehnke N, Correa S, Hao L, Wang W, Straehla JP, Bhatia SN, Hammond PT. 2020. Theranostic Layer-by-Layer Nanoparticles for Simultaneous Tumor Detection and Gene Silencing. Angew Chem Int Ed Engl 59:2776–2783.

Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, Elledge SJ, Hemann MT, Pritchard JR. 2020. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci U S A 117:4053–4060.

Buss CG, Bhatia SN. 2020. Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics. Proc Natl Acad Sci U S A 117:13428–13436.

Chatterjee N, Whitman MA, Harris CA, Min SM, Jonas O, Lien EC, Luengo A, Vander Heiden MG, Hong J, Zhou P, Hemann MT, Walker GC. 2020. REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks. Proc Natl Acad Sci U S A 117:28918–28921.

Gupta M, Concepcion CP, Fahey CG, Keshishian H, Bhutkar A, Brainson CF, Sanchez-Rivera FJ, Pessina P, Kim JY, Simoneau A, Paschini M, Beytagh MC, Stanclift CR, Schenone M, Mani DR, Li C, Oh A, Li F, Hu H, Karatza A, Bronson RT, Shaw AT, Hata AN, Wong K-K, Zou L, Carr SA, Jacks T, Kim CF. 2020. BRG1 loss predisposes lung cancers to replicative stress and ATR dependency. Cancer Res 80.

Hebert JD, Myers SA, Naba A, Abbruzzese G, Lamar JM, Carr SA, Hynes RO. 2020a. Proteomic Profiling of the ECM of Xenograft Breast Cancer Metastases in Different Organs Reveals Distinct Metastatic Niches. Cancer Res 80:1475–1485.

Hebert JD, Tian C, Lamar JM, Rickelt S, Abbruzzese G, Liu X, Hynes RO. 2020b. The scaffold protein IQGAP1 is crucial for extravasation and metastasis. Sci Rep 10.

Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su M-J, Shah P, Iwanicki M, Walker SR, Kanodia A, Melms JC, Mei S, Lin J-R, Porter CBM, Slyper M, Waldman J, Jerby-Arnon L, Ashenberg O, Brinker TJ, Mills C, Rogava M, Vigneau S, Sorger PK, Garraway LA, Konstantinopoulos PA, Liu JF, Matulonis U, Johnson BE, Rozenblatt-Rosen O, Rotem A, Regev A. 2020. A single-cell landscape of high-grade serous ovarian cancer. Nat Med 26:1271–1279.

Jin X, Demere Z, Nair K, Ali A, Ferraro GB, Natoli T, Deik A, Petronio L, Tang AA, Zhu C, Wang L, Rosenberg D, Mangena V, Roth J, Chung K, Jain RK, Clish CB, Vander Heiden MG, Golub TR. 2020. A metastasis map of human cancer cell lines. Nature 588:331–336.

Kang JH, Katsikis G, Li Z, Sapp KM, Stockslager MA, Lim D, Vander Heiden MG, Yaffe MB, Manalis SR, Miettinen TP. 2020. Monitoring and modeling of lymphocytic leukemia cell bioenergetics reveals decreased ATP synthesis during cell division. Nat Commun 11:4983.

Karthaus WR, Hofree M, Choi D, Linton EL, Turkekul M, Bejnood A, Carver B, Gopalan A, Abida W, Laudone V, Biton M, Chaudhary O, Xu T, Masilionis I, Manova K, Mazutis L, Pe’er D, Regev A, Sawyers CL. 2020. Regenerative potential of prostate luminal cells revealed by single-cell analysis. Science 368:497–505.

Kirkpatrick JD, Warren AD, Soleimany AP, Westcott PMK, Voog JC, Martin-Alonso C, Fleming HE, Tammela T, Jacks T, Bhatia SN. 2020. Urinary detection of lung cancer in mice via noninvasive pulmonary protease profiling. Sci Transl Med 12.

Lau AN, Li Z, Danai LV, Westermark AM, Darnell AM, Ferreira R, Gocheva V, Sivanand S, Lien EC, Sapp KM, Mayers JR, Biffi G, Chin CR, Davidson SM, Tuveson DA, Jacks T, Matheson NJ, Yilmaz O, Vander Heiden MG. 2020. Dissecting cell type-specific metabolism in pancreatic ductal adenocarcinoma. eLife 9:e56782.

Lau AN, Vander Heiden MG. 2020. Metabolism in the Tumor Microenvironment. Annu Rev Cancer Biol 4:17–40.

Liu VM, Howell AJ, Hosios AM, Li Z, Israelsen WJ, Heiden MGV. 2020. Cancer-associated mutations in human pyruvate kinase M2 impair enzyme activity. FEBS Lett 594:646–664.

Liu Y, Shi N, Regev A, He S, Hemann MT. 2020. Integrated regulatory models for inference of subtype‐specific susceptibilities in glioblastoma. Mol Syst Biol 16.

Ng SR, Rideout WM, Akama-Garren EH, Bhutkar A, Mercer KL, Schenkel JM, Bronson RT, Jacks T. 2020. CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer. Proc Natl Acad Sci U S A 117:513–521.

Ngo B, Kim E, Osorio-Vasquez V, Doll S, Bustraan S, Liang RJ, Luengo A, Davidson SM, Ali A, Ferraro GB, Fischer GM, Eskandari R, Kang DS, Ni J, Plasger A, Rajasekhar VK, Kastenhuber ER, Bacha S, Sriram RK, Stein BD, Bakhoum SF, Snuderl M, Cotzia P, Healey JH, Mainolfi N, Suri V, Friedman A, Manfredi M, Sabatini DM, Jones DR, Yu M, Zhao JJ, Jain RK, Keshari KR, Davies MA, Heiden MGV, Hernando E, Mann M, Cantley LC, Pacold ME. 2020. Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov 10:1352–1373.

Replogle JM, Zhou W, Amaro AE, McFarland JM, Villalobos-Ortiz M, Ryan J, Letai A, Yilmaz O, Sheltzer J, Lippard SJ, Ben-David U, Amon A. 2020. Aneuploidy increases resistance to chemotherapeutics by antagonizing cell division. Proc Natl Acad Sci USA 117:30566–30576.

Rickelt S, Condon C, Mana M, Whittaker C, Pfirschke C, Roper J, Patil DT, Brown I, Mattia AR, Zukerberg L, Zhao Q, Chetty R, Lauwers GY, Neyaz A, Leijssen LGJ, Boylan K, Yilmaz OH, Deshpande V, Hynes RO. 2020. Agrin in the Muscularis Mucosa Serves as a Biomarker Distinguishing Hyperplastic Polyps from Sessile Serrated Lesions. Clin Cancer Res 26:1277–1287.

Romero R, Sánchez-Rivera FJ, Westcott PMK, Mercer KL, Bhutkar A, Muir A, González Robles TJ, Lamboy Rodríguez S, Liao LZ, Ng SR, Li L, Colón CI, Naranjo S, Beytagh MC, Lewis CA, Hsu PP, Bronson RT, Vander Heiden MG, Jacks T. 2020. Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1. Nature Cancer 1:589–602.

Schuerle S, Furubayashi M, Soleimany AP, Gwisai T, Huang W, Voigt C, Bhatia SN. 2020. Genetic Encoding of Targeted Magnetic Resonance Imaging Contrast Agents for Tumor Imaging. ACS Synth Biol 9:392–401.

Sivanand S, Vander Heiden MG. 2020. Emerging Roles for Branched-Chain Amino Acid Metabolism in Cancer. Cancer Cell 37:147–156.

Sivanand S, Vander Heiden MG. 2020. Transcriptional activation of macropinocytosis by the Hippo pathway following nutrient limitation. Genes Dev 34:1253–1255.

Soleimany AP, Kirkpatrick JD, Su S, Dudani JS, Zhong Q, Bekdemir A, Bhatia SN. 2020. Activatable zymography probes enable in situ localization of protease dysregulation in cancer. Cancer Res.

Terhorst A, Sandikci A, Keller A, Whittaker CA, Dunham MJ, Amon A. 2020. The environmental stress response causes ribosome loss in aneuploid yeast cells. Proc Natl Acad Sci U S A 117:17031–17040.

Tian C, Öhlund D, Rickelt S, Lidström T, Huang Y, Hao L, Zhao RT, Franklin O, Bhatia SN, Tuveson DA, Hynes RO. 2020. Cancer Cell–Derived Matrisome Proteins Promote Metastasis in Pancreatic Ductal Adenocarcinoma. Cancer Res 80:1461–1474.

Urbanska M, Muñoz HE, Shaw Bagnall J, Otto O, Manalis SR, Di Carlo D, Guck J. 2020. A comparison of microfluidic methods for high-throughput cell deformability measurements. Nat Methods 17:587–593.

van Gastel N, Spinelli JB, Sharda A, Schajnovitz A, Baryawno N, Rhee C, Oki T, Grace E, Soled HJ, Milosevic J, Sykes DB, Hsu PP, Vander Heiden MG, Vidoudez C, Trauger SA, Haigis MC, Scadden DT. 2020. Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance. Cell Metabolism 32:391-403.e6.

Vassel F-M, Bian K, Walker GC, Hemann MT. 2020. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Proc Natl Acad Sci U S A.

Zhang S, Iyer S, Ran H, Dolgalev I, Gu S, Wei W, Foster CJR, Loomis CA, Olvera N, Dao F, Levine DA, Weinberg RA, Neel BG. 2020. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Cancer Discov.

Zou Y, Henry WS, Ricq EL, Graham ET, Phadnis VV, Maretich P, Paradkar S, Boehnke N, Deik AA, Reinhardt F, Eaton JK, Ferguson B, Wang W, Fairman J, Keys HR, Dančík V, Clish CB, Clemons PA, Hammond PT, Boyer LA, Weinberg RA, Schreiber SL. 2020. Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature 585:603–608.

Back to top of page

2019

Babic A, Rosenthal MH, Bamlet WR, Takahashi N, Sugimoto M, Danai LV, Morales-Oyarvide V, Khalaf N, Dunne RF, Brais LK, Welch MW, Zellers CL, Dennis C, Rifai N, Prado CM, Caan B, Sundaresan TK, Meyerhardt JA, Kulke MH, Clish CB, Ng K, Heiden MGV, Petersen GM, Wolpin BM. 2019. Post diagnosis loss of skeletal muscle, but not adipose tissue, is associated with shorter survival of patients with advanced pancreatic cancer. Cancer Epidemiol Biomarkers Prev cebp.0370.2019.

Cheng C-W, Biton M, Haber AL, Gunduz N, Eng G, Gaynor LT, Tripathi S, Calibasi-Kocal G, Rickelt S, Butty VL, Moreno-Serrano M, Iqbal AM, Bauer-Rowe KE, Imada S, Ulutas MS, Mylonas C, Whary MT, Levine SS, Basbinar Y, Hynes RO, Mino-Kenudson M, Deshpande V, Boyer LA, Fox JG, Terranova C, Rai K, Piwnica-Worms H, Mihaylova MM, Regev A, Yilmaz ÖH. 2019. Ketone Body Signaling Mediates Intestinal Stem Cell Homeostasis and Adaptation to Diet. Cell 178:1115-1131.e15.

Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, Fenoglio S, Luengo A, Lees JA, Heiden MGV, Lauffenburger DA, Hemann MT. 2019. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Res 79:5723–5733.

Derynck R, Weinberg RA. 2019. EMT and Cancer: More Than Meets the Eye. Developmental Cell 49:313–316.

Diehl FF, Lewis CA, Fiske BP, Vander Heiden MG. 2019. Cellular redox state constrains serine synthesis and nucleotide production to impact cell proliferation. Nat Metab 1:861–867.

Dongre A, Weinberg RA. 2019. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol 20:69–84.

Hamza B, Ng SR, Prakadan SM, Delgado FF, Chin CR, King EM, Yang LF, Davidson SM, DeGouveia KL, Cermak N, Navia AW, Winter PS, Drake RS, Tammela T, Li CM-C, Papagiannakopoulos T, Gupta AJ, Shaw Bagnall J, Knudsen SM, Vander Heiden MG, Wasserman SC, Jacks T, Shalek AK, Manalis SR. 2019. Optofluidic real-time cell sorter for longitudinal CTC studies in mouse models of cancer. Proc Natl Acad Sci U S A 116:2232–2236.

Jailkhani N, Ingram JR, Rashidian M, Rickelt S, Tian C, Mak H, Jiang Z, Ploegh HL, Hynes RO. 2019. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci U S A 116:14181–14190.

Jain PK, Lo JH, Rananaware S, Downing M, Panda A, Tai M, Raghavan S, Fleming HE, Bhatia SN. 2019. Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes. Nanoscale 11:21317–21323.

Kang JH, Miettinen TP, Chen L, Olcum S, Katsikis G, Doyle PS, Manalis SR. 2019. Non-invasive monitoring of single-cell mechanics by acoustic scattering. Nat Methods 16:263–269.

Lamar JM, Xiao Y, Norton E, Jiang Z-G, Gerhard GM, Kooner S, Warren JSA, Hynes RO. 2019. SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis. J Biol Chem 294:2302–2317.

Li L, Ng SR, Colón CI, Drapkin BJ, Hsu PP, Li Z, Nabel CS, Lewis CA, Romero R, Mercer KL, Bhutkar A, Phat S, Myers DT, Muzumdar MD, Westcott PMK, Beytagh MC, Farago AF, Heiden MGV, Dyson NJ, Jacks T. 2019. Identification of DHODH as a therapeutic target in small cell lung cancer. Sci Transl Med 11.

Lien EC, Vander Heiden MG. 2019. A framework for examining how diet impacts tumour metabolism. Nat Rev Cancer.

Loynachan C, Soleimany AP, Dudani JS, Lin Y, Najer A, Bekdemir A, Chen Q, Bhatia SN, Stevens M. 2019. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring. Nat Nanotech 883–890.

Mattaini KR, Sullivan MR, Lau AN, Fiske BP, Bronson RT, Vander Heiden MG. 2019. Increased PHGDH expression promotes aberrant melanin accumulation. BMC Cancer 19.

Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Castro LNG, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, Small J, Pelton K, Becker S, Bonal D, Nguyen Q-D, Servis RL, Fung JM, Mylvaganam R, Mayr L, Gojo J, Haberler C, Geyeregger R, Czech T, Slavc I, Nahed BV, Curry WT, Carter BS, Wakimoto H, Brastianos PK, Batchelor TT, Stemmer-Rachamimov A, Martinez-Lage M, Frosch MP, Stamenkovic I, Riggi N, Rheinbay E, Monje M, Rozenblatt-Rosen O, Cahill DP, Patel AP, Hunter T, Verma IM, Ligon KL, Louis DN, Regev A, Bernstein BE, Tirosh I, Suvà ML. 2019. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 178:835-849.e21.

Rashidian M, LaFleur MW, Verschoor VL, Dongre A, Zhang Y, Nguyen TH, Kolifrath S, Aref AR, Lau CJ, Paweletz CP, Bu X, Freeman GJ, Barrasa MI, Weinberg RA, Sharpe AH, Ploegh HL. 2019. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proc Natl Acad Sci U S A 116:16971–16980.

Schmidt L, Eskiocak B, Kohn R, Dang C, Joshi NS, DuPage M, Lee D-Y, Jacks T. 2019. Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation. Proc Natl Acad Sci U S A 116:17460–17469.

Shibue T, Reinhardt F, Weinberg RA. 2019. Syndecan-Mediated Ligation of ECM Proteins Triggers Proliferative Arrest of Disseminated Tumor Cells. Cancer Res 79:5944–5957.

Struntz NB, Chen A, Deutzmann A, Wilson RM, Stefan E, Evans HL, Ramirez MA, Liang T, Caballero F, Wildschut MHE, Neel DV, Freeman DB, Pop MS, McConkey M, Muller S, Curtin BH, Tseng H, Frombach KR, Butty VL, Levine SS, Feau C, Elmiligy S, Hong JA, Lewis TA, Vetere A, Clemons PA, Malstrom SE, Ebert BL, Lin CY, Felsher DW, Koehler AN. 2019. Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription. Cell Chem Biol 26:711-723.e14.

Sullivan Mark R, Danai LV, Lewis CA, Chan SH, Gui DY, Kunchok T, Dennstedt EA, Vander Heiden MG, Muir A. 2019. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. eLife 8:e44235.

Sullivan Mark R., Mattaini KR, Dennstedt EA, Nguyen AA, Sivanand S, Reilly MF, Meeth K, Muir A, Darnell AM, Bosenberg MW, Lewis CA, Vander Heiden MG. 2019. Increased Serine Synthesis Provides an Advantage for Tumors Arising in Tissues Where Serine Levels Are Limiting. Cell Metabolism 29:1410-1421.e4.

Sullivan MR, Vander Heiden MG. 2019. Determinants of nutrient limitation in cancer. Crit Rev Biochem Mol Biol 54:193–207.

Tian C, Clauser KR, Öhlund D, Rickelt S, Huang Y, Gupta M, Mani DR, Carr SA, Tuveson DA, Hynes RO. 2019. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells. Proc Natl Acad Sci U S A 116:19609–19618.

van de Kooij B, Creixell P, van Vlimmeren A, Joughin BA, Miller CJ, Haider N, Simpson CD, Linding R, Stambolic V, Turk BE, Yaffe MB. 2019. Comprehensive substrate specificity profiling of the human Nek kinome reveals unexpected signaling outputs. eLife 8:e44635.

Venkatesh HS, Morishita W, Geraghty AC, Silverbush D, Gillespie SM, Arzt M, Tam LT, Espenel C, Ponnuswami A, Ni L, Woo PJ, Taylor KR, Agarwal A, Regev A, Brang D, Vogel H, Hervey-Jumper S, Bergles DE, Suvà ML, Malenka RC, Monje M. 2019. Electrical and synaptic integration of glioma into neural circuits. Nature 573:539–545.

Back to top of page

2018

Alkan HF, Walter KE, Luengo A, Madreiter-Sokolowski CT, Stryeck S, Lau AN, Al-Zoughbi W, Lewis CA, Thomas CJ, Hoefler G, et al. 2018. Cytosolic aspartate availability determines cell survival when glutamine is limiting. Cell Metab 28: 706-720.e6.

Brabletz T, Kalluri R, Nieto MA, Weinberg RA. 2018. EMT in cancer. Nat Rev Cancer 18: 128–134.

Castaño Z, Juan BPS, Spiegel A, Pant A, DeCristo MJ, Laszewski T, Ubellacker JM, Janssen SR, Dongre A, Reinhardt F, et al. 2018. IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat Cell Biol 20: 1084–1097.

Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A, Lien EC, Mayers JR, Tai K, Lau AN, Jones-Sali P, et al. 2018. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558: 600–604.

Dayton TL, Gocheva V, Miller KM, Bhutkar A, Lewis CA, Bronson RT, Vander Heiden MG, Jacks T. 2018. Isoform-specific deletion of PKM2 constrains tumor initiation in a mouse model of soft tissue sarcoma. Cancer Metab 6

Dexter JP, Ward PS, Dasgupta T, Hosios AM, Gunawardena J, Vander Heiden MG. 2018. Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate. J Biol Chem 293: 20051–20061.

Dudani JS, Ibrahim M, Kirkpatrick J, Warren AD, Bhatia SN. 2018. Classification of prostate cancer using a protease activity nanosensor library. Proc Natl Acad Sci U S A 115: 8954–8959.

Filbin MG, Tirosh I, Hovestadt V, Shaw ML, Escalante LE, Mathewson ND, Neftel C, Frank N, Pelton K, Hebert CM, et al. 2018. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science 360: 331–335.

Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, et al. 2018. Height, obesity, and the risk of TMPRSS2:ERG-defined prostate cancer. Cancer Epidemiol Biomarkers Prev 27: 193–200.

Hillis AL, Lau AN, Devoe CX, Dayton TL, Danai LV, Di Vizio D, Vander Heiden MG. 2018. PKM2 is not required for pancreatic ductal adenocarcinoma. Cancer Metab 6

Hosios AM, Vander Heiden MG. 2018. The redox requirements of proliferating mammalian cells. J Biol Chem 293: 7490–7498.

Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su M-J, Melms JC, Leeson R, Kanodia A, Mei S, Lin J-R, et al. 2018. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175: 984-997.e24.

Kauke MJ, Tisdale AW, Kelly RL, Braun CJ, Hemann MT, Wittrup KD. 2018. A Raf-competitive K-Ras binder can fail to functionally antagonize signaling. Mol Cancer Ther 17: 1773–1780.

Krall JA, Reinhardt F, Mercury OA, Pattabiraman DR, Brooks MW, Dougan M, Lambert AW, Bierie B, Ploegh HL, Dougan SK, et al. 2018. The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy. Sci Transl Med 10

Leifer BS, Doyle SK, Richters A, Evans HL, Koehler AN. 2018. Chapter Nine - An array-based ligand discovery platform for proteins with short half-lives. In Methods in Enzymology (ed. C.A. Lesburg), Vol. 610 of Modern Approaches in Drug Discovery, pp. 191–218, Academic Press 

Muir A, Danai LV, Vander Heiden MGV. 2018. Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies. Dis Model Mech 11.

Muir A, Vander Heiden MG. 2018. The nutrient microenvironment affects cancer therapy. Science 360: 962–963.

Rickelt S, Hynes RO. 2018. Antibodies and methods for immunohistochemistry of extracellular matrix proteins. Matrix Biology 71–72: 10–27.

Sullivan LB, Luengo A, Danai LV, Bush LN, Diehl FF, Hosios AM, Lau AN, Elmiligy S, Malstrom S, Lewis CA, et al. 2018. Aspartate is an endogenous metabolic limitation for tumour growth. Nat Cell Biol 20: 782–788.

Vandekeere S, Dubois C, Kalucka J, Sullivan MR, García-Caballero M, Goveia J, Chen R, Diehl FF, Bar-Lev L, Souffreau J, et al. 2018. Serine synthesis via PHGDH is essential for Heme production in endothelial cells. Cell Metabolism 28: 573-587.e13.

Viswanathan SR, Nogueira MF, Buss CG, Krill-Burger JM, Wawer MJ, Malolepsza E, Berger AC, Choi PS, Shih J, Taylor AM, et al. 2018. Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer. Nat Genet 50: 937–943.

Zhang Y, Weinberg RA. 2018a. Epithelial-to-mesenchymal transition in cancer: complexity and opportunities. Front Med 12: 361–373.

Back to top of page

2017

Benjamin DC, Hynes RO. 2017. Intravital imaging of metastasis in adult Zebrafish. BMC Cancer 17.

Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, et al. 2017. Coordinated splicing of regulatory detained introns within oncogenic transcripts creates an exploitable vulnerability in malignant glioma. Cancer Cell 32: 411-426.e11.

Chen P-Y, Muzumdar MD, Dorans KJ, Robbins RA, Bhutkar A, Rosario AMD, Mertins P, Qiao J, Schäfer C, Gertler FB, et al. 2017. Adaptive and reversible resistance to Kras inhibition in pancreatic cancer cells. Cancer Res

Davidson SM, Vander Heiden MG. 2017b. Critical functions of the lysosome in cancer biology. Annu Rev Pharmacol Toxicol 57: 481–507.

Dongre A, Rashidian M, Reinhardt F, Bagnato A, Keckesova Z, Ploegh HL, Weinberg RA. 2017. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res 77: 3982–3989.

Engblom C, Pfirschke C, Zilionis R, Martins J da S, Bos SA, Courties G, Rickelt S, Severe N, Baryawno N, Faget J, et al. 2017. Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358

Feng Y-X, Jin DX, Sokol ES, Reinhardt F, Miller DH, Gupta PB. 2017. Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1. Nat Commun 8

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, et al. 2017. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med 23: 301–313.

Gocheva V, Naba A, Bhutkar A, Guardia T, Miller KM, Li CM-C, Dayton TL, Sanchez-Rivera FJ, Kim-Kiselak C, Jailkhani N, et al. 2017. Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A 114: E5625–E5634.

Guen VJ, Chavarria TE, Kröger C, Ye X, Weinberg RA, Lees JA. 2017. EMT programs promote basal mammary stem cell and tumor-initiating cell stemness by inducing primary ciliogenesis and Hedgehog signaling. Proc Natl Acad Sci U S A114: E10532–E10539.

Keckesova Z, Donaher JL, De Cock J, Freinkman E, Lingrell S, Bachovchin DA, Bierie B, Tischler V, Noske A, Okondo MC, et al. 2017. LACTB is a tumour suppressor that modulates lipid metabolism and cell state. Nature 543: 681–686.

Kwan BH, Zhu EF, Tzeng A, Sugito HR, Eltahir AA, Ma B, Delaney MK, Murphy PA, Kauke MJ, Angelini A, et al. 2017. Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. J Exp Med 214: 1679–1690.

Kwon EJ, Dudani JS, Bhatia SN. 2017. Ultrasensitive tumour-penetrating nanosensors of protease activity. Nat Biomed Eng1

Lagarrigue F, Gertler FB, Ginsberg MH, Cantor JM. 2017. Loss of T cell RIAM precludes conjugate formation with antigen-presenting cells and prevents immune-mediated diabetes. J Immunol 198: 3410–3415.

Lambert AW, Pattabiraman DR, Weinberg RA. 2017. Emerging biological principles of metastasis. Cell 168: 670–691.

Lau AN, Israelsen WJ, Roper J, Sinnamon MJ, Georgeon L, Dayton TL, Hillis AL, Yilmaz OH, Di Vizio D, Hung KE, et al. 2017. PKM2 is not required for colon cancer initiated by APC loss. Cancer Metab 5

Luengo A, Gui DY, Vander Heiden MG. 2017. Targeting metabolism for cancer therapy. Cell Chem Biol 24: 1161–1180.

Mayers JR, Heiden MGV. 2017. Nature and nurture: What determines tumor metabolic phenotypes? Cancer Res 77: 3131–3134.

Muir A, Danai LV, Gui DY, Waingarten CY, Lewis CA, Vander Heiden MG. 2017b. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition. Elife 6.

Naba A, Clauser KR, Mani DR, Carr SA, Hynes RO. 2017. Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression. Sci Rep 7

Olenchock BA, Rathmell JC, Vander Heiden MG. 2017. Biochemical underpinnings of immune cell metabolic phenotypes.Immunity 46: 703–713.

Olivares O, Mayers JR, Gouirand V, Torrence ME, Gicquel T, Borge L, Lac S, Roques J, Lavaut M-N, Berthezène P, et al. 2017. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat Commun 8

Oudin MJ, Barbier L, Schäfer C, Kosciuk T, Miller MA, Han S, Jonas O, Lauffenburger DA, Gertler FB. 2017. MENA confers resistance to paclitaxel in triple-negative breast cancer. Mol Cancer Ther 16:143–155.

Rashidian M, Ingram JR, Dougan M, Dongre A, Whang KA, LeGall C, Cragnolini JJ, Bierie B, Gostissa M, Gorman J, et al. 2017. Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med214: 2243–2255.

Ren Y, Sagers JE, Landegger LD, Bhatia SN, Stankovic KM. 2017. Tumor-penetrating delivery of siRNA against TNFα to human vestibular schwannomas. Sci Rep 7

Roper J, Tammela T, Cetinbas NM, Akkad A, Roghanian A, Rickelt S, Almeqdadi M, Wu K, Oberli M, Sánchez-Rivera F, et al. 2017. In vivo genome editing and organoid transplantation models of colorectal cancer. Nat Biotechnol 35: 569–576.

Santaguida S, Richardson A, Iyer DR, M’Saad O, Zasadil L, Knouse KA, Wong YL, Rhind N, Desai A, Amon A. 2017. Chromosome mis-segregation generates cell-cycle-arrested cells with complex karyotypes that are eliminated by the immune system. Dev Cell 41: 638-651.e5.

Shibue T, Weinberg RA. 2017b. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol 14: 611–629.

Sokol ES, Feng Y-X, Jin DX, Tizabi MD, Miller DH, Cohen MA, Sanduja S, Reinhardt F, Pandey J, Superville DA, et al. 2017. SMARCE1 is required for the invasive progression of in situ cancers. Proc Natl Acad Sci U S A 114: 4153–4158.

Soto-Feliciano YM, Bartlebaugh JME, Liu Y, Sánchez-Rivera FJ, Bhutkar A, Weintraub AS, Buenrostro JD, Cheng CS, Regev A, Jacks TE, Young RA, Hemann MT. 2017. PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes Dev 31:973–989.

Tang Y-C, Yuwen H, Wang K, Bruno PM, Bullock K, Deik A, Santaguida S, Trakala M, Pfau SJ, Zhong N, et al. 2017. Aneuploid cell survival relies upon sphingolipid homeostasis. Cancer Res.

Vander Heiden MG, DeBerardinis RJ. 2017. Understanding the intersections between metabolism and cancer biology. Cell 168: 657–669.

Venteicher AS, Tirosh I, Hebert C, Yizhak K, Neftel C, Filbin MG, Hovestadt V, Escalante LE, Shaw ML, Rodman C, et al. 2017. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science355

Vidaki M, Drees F, Saxena T, Lanslots E, Taliaferro MJ, Tatarakis A, Burge CB, Wang ET, Gertler FB. 2017. A requirement for Mena, an actin regulator, in local mRNA translation in developing neurons. Neuron 95: 608-622.e5.

Back to top of page

2016

Balsamo M, Mondal C, Carmona G, McClain LM, Riquelme DN, Tadros J, Ma D, Vasile E, Condeelis JS, Lauffenburger DA, et al. 2016a. The alternatively-included 11a sequence modifies the effects of Mena on actin cytoskeletal organization and cell behavior. Sci Rep 6.

Carmona G, Perera U, Gillett C, Naba A, Law A-L, Sharma VP, Wang J, Wyckoff J, Balsamo M, Mosis F, et al. 2016. Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. Oncogene 35: 5155–5169.

Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, Luengo A, Bauer MR, Jha AK, O’Brien JP, Pierce KA, et al. 2016. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab 23: 517–528.

Dimitrova N, Gocheva V, Bhutkar A, Resnick R, Jong RM, Miller KM, Bendor J, Jacks T. 2016. Stromal expression of miR-143/145 promotes neoangiogenesis in lung cancer development. Cancer Discov 6: 188–201.

Din MO, Danino T, Prindle A, Skalak M, Selimkhanov J, Allen K, Julio E, Atolia E, Tsimring LS, Bhatia SN, et al. 2016. Synchronized cycles of bacterial lysis for in vivo delivery. Nature 536: 81–85.

Ferretti R, Bhutkar A, McNamara MC, Lees JA. 2016. BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance. Genes Dev 30: 18–33.

Gui DY, Sullivan LB, Luengo A, Hosios AM, Bush LN, Gitego N, Davidson SM, Freinkman E, Thomas CJ, Vander Heiden MG. 2016. Environment dictates dependence on mitochondrial complex I for NAD+ and aspartate production and determines cancer cell sensitivity to metformin. Cell Metab 24: 716–727.

Hecht VC, Sullivan LB, Kimmerling RJ, Kim D-H, Hosios AM, Stockslager MA, Stevens MM, Kang JH, Wirtz D, Vander Heiden MG, et al. 2016. Biophysical changes reduce energetic demand in growth factor–deprived lymphocytes. J Cell Biol 212: 439–447.

Jain PK, Ramanan V, Schepers AG, Dalvie NS, Panda A, Fleming HE, Bhatia SN. 2016. Development of light-activated CRISPR using photocleavable protectors of guide RNAs. Angew Chem Int Ed Engl 55: 12440–12444.

Jonas O, Oudin MJ, Kosciuk T, Whitman M, Gertler FB, Cima MJ, Flaherty KT, Langer R. 2016. Parallel in-vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities. Clin Cancer Res 22:6031–6038.

Keibler MA, Wasylenko TM, Kelleher JK, Iliopoulos O, Vander Heiden MG, Stephanopoulos G. 2016. Metabolic requirements for cancer cell proliferation. Cancer Metab 4

Mattaini KR, Sullivan MR, Vander Heiden MG. 2016. The importance of serine metabolism in cancer. J Cell Biol 214: 249–257.

Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, Bauer MR, Lau AN, Ji BW, Dixit PD, Hosios AM, et al. 2016. Tissue-of-origin Dictates Branched-Chain Amino Acid Metabolism in Mutant Kras-driven Cancers. Science 353: 1161–1165.

Miller CL, Muthupalani S, Shen Z, Drees F, Ge Z, Feng Y, Chen X, Gong G, Nagar KK, Wang TC, et al. 2016. Lamellipodin-Deficient Mice: A Model of Rectal Carcinoma. PLoS One 11.

Muzumdar MD, Dorans KJ, Chung KM, Robbins R, Tammela T, Gocheva V, Li CM-C, Jacks T. 2016. Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. Nat Commun 7.

Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO. 2016. The extracellular matrix: tools and insights for the “omics” era. Matrix Biol 49: 10–24.

Oudin MJ, Hughes SK, Rohani N, Moufarrej MN, Jones JG, Condeelis JS, Lauffenburger DA, Gertler FB. 2016a. Characterization of the expression of the pro-metastatic MenaINV isoform during breast tumor progression. Clin Exp Metastasis 33: 249–261.

Oudin MJ, Jonas O, Kosciuk T, Broye LC, Guido BC, Wyckoff J, Riquelme D, Lamar JM, Asokan SB, Whittaker C, et al. 2016b. Tumor cell-driven extracellular matrix remodeling drives haptotaxis during metastatic progression. Cancer Discov 6: 516–531.

Pattabiraman DR, Bierie B, Kober KI, Thiru P, Krall J, Zill C, Reinhardt F, Tam WL, Weinberg RA. 2016. Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability. Science 351: aad3680.

Pattabiraman DR, Weinberg RA. 2016. Targeting the Epithelial-to-Mesenchymal Transition: The Case for Differentiation-Based Therapy. Cold Spring Harb Symp Quant Biol 81: 11–19.

Pucci F, Rickelt S, Newton AP, Garris C, Nunes E, Evavold C, Pfirschke C, Engblom C, Mino-Kenudson M, Hynes RO, et al. 2016. PF4 promotes platelet production and lung cancer growth. Cell Rep 17: 1764–1772.

Schuerle S, Dudani JS, Christiansen MG, Anikeeva P, Bhatia SN. 2016. Magnetically actuated protease sensors for in vivo tumor profiling. Nano Lett 16: 6303–6310.

Spiegel A, Brooks MW, Houshyar S, Reinhardt F, Ardolino M, Fessler E, Chen MB, Krall JA, DeCock J, Zervantonakis IK, et al. 2016b. Neutrophils suppress intraluminal NK-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov 6: 630–649.

Sullivan LB, Gui DY, Heiden MGV. 2016. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy. Nat Rev Cancer 16: 680–693.

Taliaferro JM, Vidaki M, Oliveira R, Olson S, Zhan L, Saxena T, Wang ET, Graveley BR, Gertler FB, Swanson MS, et al. 2016. Distal alternative last exons localize mRNAs to neural projections. Mol Cell 61: 821–833.

Back to top of page

2015

Danino T, Prindle A, Kwong GA, Skalak M, Li H, Allen K, Hasty J, Bhatia SN. 2015. Programmable probiotics for detection of cancer in urine. Sci Transl Med 7: 289ra84.

Hughes SK, Oudin MJ, Tadros J, Neil J, Del Rosario A, Joughin BA, Ritsma L, Wyckoff J, Vasile E, Eddy R, et al. 2015. PTP1B-dependent regulation of receptor tyrosine kinase signaling by the actin-binding protein Mena. Mol Biol Cell 26: 3867–3878.

Klapproth S, Sperandio M, Pinheiro EM, Prünster M, Soehnlein O, Gertler FB, Fässler R, Moser M. 2015a. Loss of the Rap1 effector RIAM results in leukocyte adhesion deficiency due to impaired β2 integrin function in mice. Blood 126: 2704–2712.

Lau AN, Vander Heiden MG. 2015. Stopping the clock with MYC. Molecular Cell 60: 511–513.

Lee SY, Gertler FB, Goldberg MB. 2015. Vasodilator-stimulated phosphoprotein restricts cell-to-cell spread of Shigella flexneri at the cell periphery. Microbiology 161: 2149–2160.

Li CM-C, Gocheva V, Oudin MJ, Bhutkar A, Wang SY, Date SR, Ng SR, Whittaker CA, Bronson RT, Snyder EL, et al. 2015. Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes Dev 29: 1850–1862.

Naba A, Clauser KR, Hynes RO. 2015. Enrichment of extracellular matrix proteins from tissues and digestion into peptides for mass spectrometry analysis. J Vis Exp

Reticker-Flynn NE, Bhatia SN. 2015. Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov 5: 168–181.

Riquelme DN, Meyer AS, Barzik M, Keating A, Gertler FB. 2015. Selectivity in subunit composition of Ena/VASP tetramers. Biosci Rep 35

Sánchez-Rivera FJ, Jacks T. 2015. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 15: 387–395.

Su W, Wynne J, Pinheiro EM, Strazza M, Mor A, Montenont E, Berger J, Paul DS, Bergmeier W, Gertler FB, et al. 2015. Rap1 and its effector RIAM are required for lymphocyte trafficking. Blood 126: 2695–2703.

Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Eaton E, Weinberg RA. 2015. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 525: 256–260.

Ye X, Weinberg RA. 2015. Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol 25: 675–686.

Back to top of page

2014

Dimitrova N, Zamudio JR, Jong RM, Soukup D, Resnick R, Sarma K, Ward AJ, Raj A, Lee J, Sharp PA, et al. 2014. LincRNA-p21 activates p21 in cis to promote Polycomb target gene expression and to enforce the G1/S checkpoint. Mol Cell 54: 777–790.

Labelle M, Begum S, Hynes RO. 2014. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A 111: E3053–E3061.

Lu H, Clauser KR, Tam WL, Fröse J, Ye X, Eaton EN, Reinhardt F, Donnenberg VS, Bhargava R, Carr SA, et al. 2014. A breast cancer stem cell niche supported by juxtacrine signaling from monocytes and macrophages. Nat Cell Biol 16: 1105–1117.

McAllister SS, Weinberg RA. 2014. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 16: 717–727.

McFadden DG, Papagiannakopoulos T, Taylor-Weiner A, Stewart C, Carter SL, Cibulskis K, Bhutkar A, McKenna A, Dooley A, Vernon A, et al. 2014. Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156: 1298–1311.

Naba A, Clauser KR, Whittaker CA, Carr SA, Tanabe KK, Hynes RO. 2014. Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC Cancer 14: 518.

Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, et al. 2014. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell 156: 590–602.

Pattabiraman DR, Weinberg RA. 2014. Tackling the cancer stem cells – what challenges do they pose? Nat Rev Drug Discov13: 497–512.

Sánchez-Rivera FJ, Papagiannakopoulos T, Romero R, Tammela T, Bauer MR, Bhutkar A, Joshi NS, Subbaraj L, Bronson RT, Xue W, et al. 2014. Rapid modeling of cooperating genetic events in cancer through somatic genome editing. Nature 516: 428–431.

Shao DD, Xue W, Krall EB, Bhutkar A, Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et al. 2014. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158: 171–184.

Back to top of page

2013

Shibue T, Brooks MW, Weinberg RA. 2013. An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell 24: 481–498.

Back to top of page

2012

Labelle M, Hynes RO. 2012. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2: 1091–1099.

Lamar JM, Stern P, Liu H, Schindler JW, Jiang Z-G, Hynes RO. 2012. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A 109: E2441–E2450.

Reticker-Flynn NE, Braga Malta DF, Winslow MM, Lamar JM, Xu MJ, Underhill GH, Hynes RO, Jacks TE, Bhatia SN. 2012. A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis. Nat Commun 3: 1122.

Shibue T, Brooks MW, Inan MF, Reinhardt F, Weinberg RA. 2012. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov 2: 706–721.

Back to top of page

2011

Gertler F, Condeelis J. 2011. Metastasis: tumor cells becoming Menacing. Trends Cell Biol 21: 81–90.

Labelle M, Begum S, Hynes RO. 2011. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20: 576–590.

Liu H, Ong S-E, Badu-Nkansah K, Schindler J, White FM, Hynes RO. 2011. CUB-domain–containing protein 1 (CDCP1) activates Src to promote melanoma metastasis. Proc Natl Acad Sci U S A 108: 1379–1384.

Roussos ET, Balsamo M, Alford SK, Wyckoff JB, Gligorijevic B, Wang Y, Pozzuto M, Stobezki R, Goswami S, Segall JE, et al. 2011. Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. J Cell Sci 124: 2120–2131.

Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, Burge CB, Gertler FB. 2011a. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 7: e1002218.

Winslow MM, Dayton TL, Verhaak RGW, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T. 2011. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473:101–104.

Back to top of page

2010

Xu L, Begum S, Barry M, Crowley D, Yang L, Bronson RT, Hynes RO. 2010. GPR56 plays varying roles in endogenous cancer progression. Clin Exp Metastasis 27: 241–249.